Skip to main content
BiotoxtechCo.,Ltd. logo

BiotoxtechCo.,Ltd. — Investor Relations & Filings

Ticker · 086040 ISIN · KR7086040003 KO Professional, scientific and technical activities
Open in API
Filings indexed 172 across all filing types
Latest filing 2022-05-16 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 086040

About BiotoxtechCo.,Ltd.

http://eng.biotoxtech.com/

Biotoxtech Co., Ltd. is a non-clinical Contract Research Organization (CRO) that provides safety and efficacy evaluation services. The company offers a comprehensive suite of GLP-compliant studies, including general toxicity, carcinogenicity, reproductive and developmental toxicity, genotoxicity, immunotoxicity, and safety pharmacology. It also conducts efficacy evaluations and provides analytical research services such as pharmacokinetics (PK/TK/ADME) and bioanalysis. Biotoxtech serves a diverse clientele developing pharmaceuticals, biomedicines, cell and gene therapies, medical devices, chemicals, agrochemicals, cosmetics, and health functional foods.

Recent filings

Filing Released Lang Actions
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company Biotoxtech (바이오톡스텍) for the first quarter of 2022 (2022.01.01-2022.03.31). It contains detailed financial statements, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-16 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 1% confidence The document is a regulatory filing from a Korean company (Biotoxtech) regarding a 'Correction Report' (정정신고) for a 'Pledge of Shares' (주식 담보제공 계약) involving a major shareholder. This type of disclosure, which details changes in collateral, debt amounts, and share pledges by major shareholders, falls under the category of capital structure and financing updates. Since it specifically relates to the pledging of shares by a major shareholder, it is classified as a Capital/Financing Update (CAP).
2022-03-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (stock pledge) of the major shareholder (Kang Jong-koo) of Biotoxtech. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-03-28 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the voting outcomes for various agenda items (financial statement approval, director appointments, etc.) at the company's 2022 Annual General Meeting. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement.
2022-03-25 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Biotoxtech. It contains key financial data, audit opinions (unqualified/proper), and financial statements for the fiscal year. While it provides summary financial data, it is a regulatory filing submitted to the KRX (Korea Exchange) to announce the completion and submission of the audit report, rather than the full, multi-page audited financial statement document itself. Therefore, it is classified as an Audit Report/Information document. FY 2021
2022-03-17 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'BioToxTech' (주식회사 바이오톡스텍) for the fiscal year ending December 31, 2021. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial report, not an announcement or a summary, and it is distinct from a full 10-K (which is a US-specific regulatory filing). In the context of the provided categories, this fits the 'Audit Report / Information' (AR) classification as it is a standalone audit report containing the audited financial statements. FY 2021
2022-03-17 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.